Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade

Several clinical trials have shown the safety and effectiveness of PD-1/PD-L1 inhibitors in neoadjuvant therapy in resectable non-small cell lung cancer (NSCLC). However, 18–83% patients can benefit from it. In this study, we aimed to assess the association of PD-L1 expression, tumor mutation burden...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuhang, Yuan, Pei, Mao, Beibei, Li, Ning, Ying, Jianming, Tao, Xiuli, Tang, Wei, Zhang, Lei, Geng, Xiao, Zhang, Fan, Xue, Qi, Wu, Lijia, Zhang, Henghui, Gao, Shugeng, He, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758728/
https://www.ncbi.nlm.nih.gov/pubmed/35027673
http://dx.doi.org/10.1038/s41698-021-00244-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758728/
https://www.ncbi.nlm.nih.gov/pubmed/35027673
http://dx.doi.org/10.1038/s41698-021-00244-6

Ejemplares similares